Artixio

Lifesciences Compliance Services In Colombia

Optimizing your regulatory journey, we ensure time-efficient and sustained compliance, driving your Life Sciences product to success in Colombia.
Artixio serves as a reliable global partner, simplifying your regulatory journey in Colombia. We have a tech-enabled, highly experienced team with local expertise that provides end-to-end support in bringing your Life Sciences product to the Colombian market successfully. We aim to efficiently support our customers right from product conceptualization to market entry and post-marketing surveillance.

Regulatory Authorities In Colombia

INVIMA

ICA

Ensure Seamless Regulatory Compliance In Colombia with Artixio

We at Artixio provide comprehensive regulatory services, including regulatory affairs, product registration, label, artwork, market access, post-market entry, and maintenance for your Life Sciences product in Colombia. Our dedicated team with 15-30 years of experience provides tailored strategies to ensure easy market access and timely compliance under the stringent regulations of INVIMA. Our regulatory strategies help you easily navigate through the robust regulatory framework of INVIMA and ICA regulations.

Why Trust Artixio with Your Regulatory Journey In Colombia?

Local expertise with 15-20 years of experience in successfully registering and maintaining 2000+ licenses
Direct access to in-house INVIMA regulatory liaisons
KPI based, continual process excellence   
Successful Approvals and Ongoing Product Lifecycle Maintenance for 200+ products
End-to-end support from concept to commercialization
Our 15-30 years of experience tech-enabled team with a regulatory intelligence-driven solution ensures sustained compliance in Colombia.
Flexible, strategic, timely, and quality submissions.
ISO 9001:2015, Quality Driven Services Platform  
Hybrid-Local-Centralized Support across Regulatory functions

Our Services

Regulatory Affairs
Product Registration
Market Access
IND (Investigational New Drug)
NDA (New Drug Application)
Regulatory Operations
Technical Writing
Regulatory Strategy
Market Access

Industries We Serve in the European Union

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

FAQs

How to approach the INVIMA in Colombia, and what are the modes of communication?
The INVIMA has its online portal for any communication known as the SPO system, or through emails and telephone. However, the foreign representatives should appoint a legal representative for communication, as INVIMA does not directly contact the foreign manufacturers.
Yes, INVIMA recognizes foreign GMP certificates, especially from known health authorities such as the FDA, EMA, PMDA, WHO, and WHO-certified authorities.
The common reasons for the delay in INVIMA Life Sciences product approval include an incomplete dossier, improper Spanish translation, lack of legal representative documents, incomplete manufacturing, packaging, and labeling details.
The fees associated with Life sciences product varies from product to product based on their risk level, such as the registration fees for pharmaceuticals ranges from USD 3,000 to 5,000, for medical devices it ranges from USD 500 to 2,000, for biologics and vaccines it ranges from USD 4,000 to 6,000 and for cosmetics and wellness products it ranges from USD 100 to 500.
The approval license validity for Life Sciences products is 10 years, and it should be renewed at least 6 months before its expiry, or else the product needs to be registered again as a new product.

Our Global Reach: Serving Life
Sciences Clients Worldwide

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

Europe

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Article

Pharma Manufacturing Booms in Hidalgo, Mexico

Pharma Manufacturing Booms in

Hildalgo had good pharmaceutical infrastructure and supply chain capabilities, but with no foreign investment...

May 2, 2025
UK Releases Amendment & Guidance on Regulations in 2024 for Medical Devices (Post-market Surveillance Requirements)

UK Releases Amendment &

In January 2025, MHRA UK released guidance on implementation of amendments to Medical Devices...

April 23, 2025
Artixio Announces Grant for Early Stage Medtech Innovators as Part of MedTech InnovateIO Initiative

Artixio Announces Grant for

HYDERABAD, India - March 27, 2024 - Artixio, a leading compliance and commercial consulting...

April 16, 2025